(Health Korea News / Lee Si-woo) Hugel, a global total medical aesthetics company, filed a complaint with the U.S. International in the ‘Investigation into unfair practices regarding the import of botulinum toxin medicines into the United States (Inv. No. 337-TA-1313)’ filed by Medytox. It was announced on the 11th that it received a Final Determination from the International Trade Commission (ITC) stating that Hugel had not committed any violations.
On the 10th local time, the ITC decided, “After reexamining the Initial Determination made on June 10, there was no violation of the Customs Act.” With this, the ITC investigation has ended.
Through a preliminary ruling, the ITC determined that “We do not support the claim of ‘strain theft’ raised by Medytox, and there is no violation of Article 337 of the U.S. Customs Act when importing specific botulinum toxin products and their manufacturing or related processes into the United States.” There is a bar.
Medytox filed this issue with the ITC against Hugel, Hugel America, and Chroma Pharma in March 2022. While the lawsuit was in progress, Medytox confirmed the evidence submitted by Hugel through the discovery process and withdrew its claims of misappropriation of trade secrets regarding botulinum strains in September and October 2023, followed by the botulinum toxin manufacturing process in January of last year. The claim of misappropriation of trade secrets was also withdrawn.
A Hugel official said, “As the ITC’s final ruling revealed that Medytox’s claim of strain theft from Hugel was groundless, uncertainty about Hugel’s U.S. business has been resolved.” He added, “Hugel will continue to solidify corporate trust and shareholder value.” We plan to make a company-wide effort. “We will continue to grow in the global market, including the United States,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
